Carbon Footprint Assessment of Orion’s Dry Powder InhalersInsights | 12/02/2021
The Carbon Life Cycle Assessment Report for Easyhaler
Orion conducted and published its first carbon footprint and a comprehensive life cycle assessment (LCA) for Easyhaler in 20201. We wanted to improve our understanding of the environmental impact of our products. The LCA is a tool to give robust information on the environmental impacts of a product to identify where reduction efforts should be focused.
Orion’s LCA looks at environmental impacts made by a product over its whole life, broken down into different stages;
|Raw material extraction|
|Use and disposal|
ORION HAVE BEEN MAKING ENVIRONMENTAL EFFORTS SINCE 1980’s
Easyhaler is one good example of our efforts since 1980’s as one of the original Easyhaler development objectives was to create a propellant-free inhaler for environmental reasons.
IN MDIs, PROPELLANTS ARE DISCHARGED DURING USE AND RELEASED AFTER PRODUCT DISPOSAL
Although CFCs were prohibited in inhaler use in 1987 by The Montreal Protocol, HFCs are still widely used as a propellant in metered dose inhalers. In MDIs, propellants are discharged during use and released after product disposal.2 These propellants, HFCs, are potent greenhouse gases with around 1300 times more global warming potential than carbon dioxide. And, the carbon footprint of single MDI products is still 10-37 times higher than dry powder inhalers (DPIs)2. Based on earlier assessments, DPIs have been reported to have carbon footprint between 1.5 and 6kg CO2e for 200-doses inhaler2.
The results represent the estimated environmental impact for creating, using and disposing the inhaler device. Several environmental indicators, such as climate change, toxicity and water depletion were assessed to ensure holistic understanding on the environmental impact.
Was this article helpful?
May 2021 / RESP-330bdl(1)
- Carbon life cycle assessment report for Orion Corporation, Orion Pharma. Executive summary. Carbon Footprint Ltd 2021. Available at: https://www.orion.fi/globalassets/documents/orion-group/sustainability/2021_04-orion-pharma-product-footprint-lca-executive-summary-v1.0.pdf
- Montreal protocol on substances that deplete the ozone layer. Medical and chemicals technical options committee. Assessment report 2018. Accessed 19th May from: https://ozone.unep.org/sites/default/files/2019-05/TEAPAS98.pdf